StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Puma Biotech (PBYI) Publishes 5-Year Analysis of Phase III ExteNET Study
November 14, 2017 5:39 AM
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced the publication of previously presented results from the ExteNET Phase III clinical trial of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Management Comments
Next Articles
Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology
November 13, 2017 6:34 PM
Puma Biotech (PBYI) PT Raised to $122 at Barclays on 3Q Report; 'Nerlynx Initial Launch Trend Encouraging, EU Decision in 1Q18'
November 10, 2017 1:10 PM
Puma Biotech (PBYI): Solid Start for NERLYNX - Cowen
November 10, 2017 7:49 AM
Puma Biotechnology (PBYI) PT Raised to $142 at Credit Suisse, 'Early Trend Indicators Stronger Trajectory'
November 10, 2017 4:56 AM
Puma Biotechnology (PBYI) PT Raised to $164 at Citi, 'Buy The Dip'
November 10, 2017 4:14 AM
